SAVA241018P35000
- 6.00
- -1.38-18.70%
Cassava Sciences Newsroom
10 Health Care Stocks With Whale Alerts In Today's Session
Cassava Sciences Call Volume Above Normal and Directionally Bullish
$1000 Invested In This Stock 5 Years Ago Would Be Worth $20,000 Today
Sector Update: Health Care Stocks Rise Late Afternoon
Cassava Sciences Completes Phase 3 ReTHINK Alzheimer's Trial
Cassava Sciences Stock Jumps After CEO's Update On Alzheimer's Drug Trial: Retail Sentiment Wavers
Crude Oil Falls Over 4%; US Trade Deficit Narrows In August
Alzheimer's-Focused Cassava Sciences +7% After SEC Settlement
PepsiCo, DocuSign, Robinhood And Other Big Stocks Moving Higher On Tuesday
This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
H.C. Wainwright Upgrades Cassava Sciences(SAVA.US) to Buy Rating, Announces Target Price $116
Express News | Cassava Shares up 6.3% Premarket After Co Decides to Settle SEC Charges on Alzheimer's Drug Trial Claims
Cassava Sciences Advances Alzheimer's Trials Amid SEC Settlement
Cassava Sciences Price Target Announced at $116.00/Share by HC Wainwright & Co.
Cassava Sciences to Announce Top-line Results of ReTHINK Trial Before Year-end
Cassava Sciences up 8% at $27.44 in Pre-market Following CEO Letter
Cassava Sciences CEO Rick Barry Issues Open Letter
Cassava Sciences Analyst Ratings
Express News | Cassava Sciences- Agreed to Settle Charge of 'negligently Making Inaccurate Disclosures' Related to 2020 Phase 2B Clinical Study